Targeting TNBC: core-shell polycationic polyurea dendrimers with inherent anticancer activity

Adriana Cruz1, Bruna Abreu2,3, Cindy Mendes2,3

  • 1iBB-Institute for Bioengineering and Biosciences, and Associate Laboratory i4HB-Institute for Health and Bioeconomy, Instituto Superior Técnico, Lisbon, Portugal.

FEBS Open Bio
|March 16, 2026
PubMed

Insights

Novel polyurea (PURE) dendrimers show promise for treating triple-negative breast cancer (TNBC). These nanostructures target cancer cells, induce cell death, and reduce tumor size in preclinical models with manageable toxicity.

Area of Science:

  • Nanotechnology
  • Oncology
  • Materials Science

Background:

  • Breast carcinoma (BC) is a prevalent cancer in women, with triple-negative breast cancer (TNBC) representing a significant subset.
  • TNBC lacks targeted therapies and exhibits poor prognosis due to late detection and metastasis.
  • Dendrimers, with their unique globular architecture, offer potential for targeted cancer therapy by interacting with cell membranes.

Purpose of the Study:

  • To evaluate the anticancer efficacy of two novel polycationic polyurea (PURE) dendrimers, PUREG4-OEI48 and PUREG4-OCEI24, against breast cancer.
  • To investigate the selective targeting and therapeutic mechanisms of these dendrimers on TNBC cells.

Main Methods:

  • Synthesis and characterization of PUREG4-OEI48 and PUREG4-OCEI24 dendrimers.
  • In vitro assessment of dendrimer interaction with TNBC cell lines, including induction of apoptosis, necroptosis, and ferroptosis.
  • In vivo evaluation of dendrimer efficacy and toxicity in a mouse xenograft model (HCC1806).

Main Results:

  • Both PURE dendrimers demonstrated selective interaction with TNBC cells.
  • Induction of multiple cell death pathways (apoptosis, necroptosis, ferroptosis) was observed in vitro.
  • In vivo studies showed significant reduction in tumor volume in HCC1806 xenografts.
  • PUREG4-OEI48 exhibited no observable toxicity, while PUREG4-OCEI24 caused mild hepatic toxicity.

Conclusions:

  • PURE dendrimers represent a promising therapeutic strategy for TNBC.
  • Further research and modifications are warranted to optimize dendrimer efficacy and minimize potential toxicity for clinical translation.

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
82
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
73